Viking Therapeutics priced concurrent offerings of 7.85 million shares at $35 each and $225 million of 2% convertible senior notes due 2032. The company expects approximately $258.2 million in net proceeds from the stock offering, or about $297 million if underwriters fully exercise their option for additional shares. Viking said the financing will support the continued clinical development, advancement and commercialization of VK2735 and VK3019, as well as research and development, working capital and general corporate purposes. Shares fell 15.61% to $35.15 at publication, although the stock remained above its 20-day and 200-day simple moving averages. Benzinga Edge assigned Viking a bullish momentum score of 89.65.